{
    "clinical_study": {
        "@rank": "6585", 
        "arm_group": [
            {
                "arm_group_label": "control", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Rubus occidentalis extract 900mg", 
                "arm_group_type": "Active Comparator", 
                "description": "taking Rubus occidentalis extract 900mg/day for 12weeks"
            }, 
            {
                "arm_group_label": "Rubus occidentalis extract 1800mg", 
                "arm_group_type": "Active Comparator", 
                "description": "taking Rubus occidentalis extract 1800mg/day for 12weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Rubus occidentalis extract could improve\n      fasting or postprandial serum glucose levels, and related metabolic markers among patients\n      with prediabetes (impaired fasting glucose and/or impaired glucose tolerance)."
        }, 
        "brief_title": "Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes", 
        "condition": "Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance)", 
        "condition_browse": {
            "mesh_term": [
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  19 years of age or older\n\n          -  prediabetes (fasting plasma glucose 100-125mg/dl, and/or post 75g OGTT plasma glucose\n             140-199mg/dl)\n\n        Exclusion Criteria:\n\n          -  pregnant women\n\n          -  taking anti-hyperglycemic agents within 3 months at the time of enrollment\n\n          -  history of heart failure, myocardial infarction, cerebral infarction\n\n          -  uncontrolled hypertension (systolic BP > 160mmHg, or diastolic BP > 100mmHg)\n\n          -  serum triglyceride level > 500mg/dl\n\n          -  kidney dysfunction (serum Creatinine > 30% of upper normal limits)\n\n          -  hepatic dysfunction (AST, ALT > 3 times of upper normal limits)\n\n          -  taking systemic glucocorticoids within 1 month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964703", 
            "org_study_id": "ED13024"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rubus occidentalis extract 900mg", 
                "Rubus occidentalis extract 1800mg"
            ], 
            "intervention_name": "Rubus occidentalis extract", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 14, 2013", 
        "number_of_arms": "3", 
        "official_title": "Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study", 
        "other_outcome": {
            "measure": "HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "serum glucose (fasting and post 75g oral glucose tolerance test)", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964703"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Korea University Anam Hospital", 
            "investigator_full_name": "Sin Gon Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "serum insulin", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "Korea University Anam Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea University Anam Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}